{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:56Z","timestamp":1793134136348,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Dasatinib is an effective treatment for Philadelphia chromosome\u2013positive (Ph+) acute leukemia, but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017), 24 adults with Ph+ acute lymphoblastic leukemia (ALL; n\u00a0=\u00a022; p190, n\u00a0=\u00a016; p210, n\u00a0=\u00a06) and chronic myeloid leukemia in lymphoid blast crisis (n\u00a0=\u00a02) were treated with escalating daily doses of asciminib in combination with dasatinib 140 mg daily plus prednisone 60\u00a0mg\/m2 daily to determine the maximum tolerated dose. After a 28-day induction, dasatinib and asciminib were continued indefinitely or until hematopoietic stem cell transplant. The median age was 64.5 years (range, 33-85; 50% aged \u226565 years). The recommended phase 2 dose of asciminib was 80 mg daily in combination with dasatinib and prednisone. The dose limiting toxicity at 160 mg daily was asymptomatic grade 3 pancreatic enzyme elevation without symptomatic pancreatitis. There were no vaso-occlusive events. Among patients with de novo ALL, the complete hematologic remission rates at days 28 and 84 were 84% and 100%, respectively. At day 84, 100% of patients achieved complete cytogenetic remission, 89% achieved measurable residual disease negativity (&amp;lt;0.01%) by multicolor flow cytometry, and 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction &amp;lt;0.1% and &amp;lt;0.01%, respectively. Dual BCR::ABL1 inhibition with dasatinib and asciminib is safe with encouraging activity in patients with de novo Ph+ ALL. This trial was registered at www.clinicaltrials.gov as #NCT02081378.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024025800","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T16:57:11Z","timestamp":1728320231000},"page":"577-589","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Asciminib plus dasatinib and prednisone for Philadelphia chromosome\u2013positive acute leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-2876","authenticated-orcid":false,"given":"Mark A.","family":"Murakami","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Keating","sequence":"additional","affiliation":[{"name":"2Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-6732","authenticated-orcid":false,"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[{"name":"2Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4515-8245","authenticated-orcid":false,"given":"Eric S.","family":"Winer","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1299-5901","authenticated-orcid":false,"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-1708","authenticated-orcid":false,"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella L.","family":"Jaeckle","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-7004","authenticated-orcid":false,"given":"Ella","family":"Hagopian","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"3Merck & Co, Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8014-706X","authenticated-orcid":false,"given":"Jessica","family":"Liegel","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"McMasters","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"5Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4997-1532","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"6Section of Hematology\/Oncology, Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2025032119474259300_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032119474259300_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2025032119474259300_bib3","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"386","author":"Foa","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2025032119474259300_bib4","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2025032119474259300_bib5","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Foa","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2025032119474259300_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2025032119474259300_bib7","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/bloodadvances.2021004813","article-title":"Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL","volume":"5","author":"Wieduwilt","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025032119474259300_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025032119474259300_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US Intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"23","key":"2025032119474259300_bib10","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025032119474259300_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/hematology.2021000226","article-title":"Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?","volume":"2021","author":"Luskin","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Prog"},{"issue":"12","key":"2025032119474259300_bib12","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025032119474259300_bib13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"2025032119474259300_bib14","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2025032119474259300_bib15","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A\u00a0phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"issue":"7647","key":"2025032119474259300_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"5","key":"2025032119474259300_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"2025032119474259300_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"2025032119474259300_bib19","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A\u00a0multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"2025032119474259300_bib20","doi-asserted-by":"crossref","first-page":"107004","DOI":"10.1016\/j.leukres.2022.107004","article-title":"Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation","volume":"125","author":"Raman","year":"2023","journal-title":"Leuk Res"},{"issue":"20","key":"2025032119474259300_bib21","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2025032119474259300_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V124.21.398.398","article-title":"ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia [abstract]","volume":"124","author":"Wylie","year":"2014","journal-title":"Blood"},{"key":"2025032119474259300_bib23","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The\u00a0specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of\u00a0its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2025032119474259300_bib24","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1182\/blood-2023-188135","article-title":"Asciminib enhances its treatment efficacy synergistically in the treatment of chronic myeloid leukemia harboring ABL1 kinase domain mutation when combined with a reduced dose of ponatinib, dasatinib, or bosutinib, but not with nilotinib or imatinib [abstract]","volume":"142","author":"Han","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025032119474259300_bib25","doi-asserted-by":"crossref","first-page":"e15929","DOI":"10.1371\/journal.pone.0015929","article-title":"Allosteric interactions between the myristate- and ATP-site of the Abl kinase","volume":"6","author":"Iacob","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2025032119474259300_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"G Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"2025032119474259300_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2025032119474259300_bib28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"2025032119474259300_bib29","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2025032119474259300_bib30","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025032119474259300_bib31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032119474259300_bib32","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7280","key":"2025032119474259300_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"issue":"46","key":"2025032119474259300_bib34","doi-asserted-by":"crossref","first-page":"e202117276","DOI":"10.1002\/anie.202117276","article-title":"Correspondence on \"synergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase\"","volume":"134","author":"Jahnke","year":"2022","journal-title":"Angew\u00a0Chem Int Ed Engl"},{"issue":"37","key":"2025032119474259300_bib36","doi-asserted-by":"crossref","first-page":"20196","DOI":"10.1002\/anie.202105351","article-title":"Synergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase","volume":"60","author":"Johnson","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"issue":"8","key":"2025032119474259300_bib37","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of\u00a0asciminib","volume":"298","author":"Oruganti","year":"2022","journal-title":"J\u00a0Biol Chem"},{"issue":"46","key":"2025032119474259300_bib38","doi-asserted-by":"crossref","first-page":"e202209518","DOI":"10.1002\/anie.202209518","article-title":"Reply to correspondence on \u201csynergy and antagonism between allosteric and active-site inhibitors of Abl tyrosine kinase\u201d","volume":"61","author":"Johnson","year":"2022","journal-title":"Angew\u00a0Chem Int Ed Engl"},{"issue":"10","key":"2025032119474259300_bib39","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood.2023022403","article-title":"Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors","volume":"143","author":"Veltmaat","year":"2024","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/blood.2025029277","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/6\/577\/2354376\/blood_bld-2024-025800-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/6\/577\/2354376\/blood_bld-2024-025800-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T17:00:19Z","timestamp":1742576419000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/6\/577\/518092\/Asciminib-plus-dasatinib-and-prednisone-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025800","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}